Q: What is AngioDynamics (ANGO) Q4 2025 Earnings Transcript Summary?
**AngioDynamics (ANGO) Q4 2025 Earnings Analysis**
AngioDynamics (ANGO) recently released its Q4 FY2025 earnings report, showcasing a mix of positive developments and challenges. Below is a summary of the key points from the earnings call:
### Bullish Points:
1. **Revenue Growth**: Total revenue increased by 12.7% year over year to $80.2 million in Q4 FY2025, with full-year revenue rising by 8.1% to $292.7 million.
2. **MedTech Segment Performance**: MedTech revenue grew by 22% to $35.8 million in Q4 FY2025, with full-year MedTech revenue up 19.5% on a pro forma basis to $126.7 million.
3. **Product-Specific Growth**:
- Mechanical thrombectomy revenue increased by 44.7% year over year in Q4 FY2025.
- AngioVac revenue grew by 39.5%, and AlphaVac revenue surged by 60.8% year over year in Q4 FY2025.
- Auryon platform revenue grew by 19.7% year over year in Q4 FY2025.
4. **Improved Margins**: Gross margin was 52.7% in Q4 FY2025, with MedTech gross margin at 59%.
5. **Cost Management**: Operating expenses decreased to $48 million, representing 60% of sales in Q4 FY2025, down from $52.9 million and 74% in the prior year quarter.
6. **Profitability Metrics**: Adjusted EBITDA increased to $3.4 million in Q4 FY2025, compared to $1.5 million in the same period of 2024.
7. **Cash Flow and Liquidity**: Free cash flow generated was $16.2 million in Q4 FY2025, with cash and cash equivalents improving to $55.9 million as of May 31, 2025.
8. **Positive Guidance**: FY2026 net sales are expected to grow 4%-6% to $305-$310 million, with MedTech sales guided to increase 12%-15%.
9. **Cost Savings Initiatives**: The company anticipates $15 million in annualized savings by FY2027 through manufacturing transitions.
10. **Regulatory and Clinical Advancements**: A CPT Category I code for NanoKnife prostate and liver ablation will be effective January 1, 2026, and clinical trials like the APeX study demonstrated positive results, such as a 35.5% clot burden reduction for AlphaVac.
### Bearish Points:
1. **Tariff Impact**: Tariff expenses of $1.6 million impacted Q4 FY2025 results, with an estimated full-year tariff impact of $4-$6 million for FY2026.
2. **NanoKnife Revenue Decline**: Total NanoKnife revenue decreased by 2.5% on a pro forma basis in Q4 FY2025 due to lower capital sales compared to the prior year.
3. **NanoKnife Capital Sales**: Capital sales for NanoKnife fell by 24.9% for the quarter.
4. **Earnings Guidance**: Adjusted loss per share guidance for FY2026 is projected to be between $(0.35) and $(0.25).
### Conclusion:
AngioDynamics demonstrated strong growth in its MedTech segment and key product lines, alongside improved margins and cash flow. However, challenges such as tariff expenses, declining NanoKnife revenue, and projected losses for FY2026 temper the overall outlook. The company's focus on cost savings, clinical advancements, and regulatory approvals could provide long-term benefits, but near-term headwinds remain a concern.
For more information about AngioDynamics' earnings call, you can read the relevant news: AngioDynamics (ANGO) Q4 2025 Earnings Transcript
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
